Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the European Commission has approved Susvimo (ranibizumab 100 mg/mL solution for injection) for the treatment of neovascular age‑related macular degeneration (nAMD), bringing the Contivue refillable implant platform – which provides continuous delivery of a customized ranibizumab formulation – to European patients.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | European Commission (EU) |
| Approval Type | Marketing authorization |
| Product | Susvimo (ranibizumab 100 mg/mL solution for injection) |
| Indication | Treatment of neovascular age-related macular degeneration (nAMD) |
| Approval Date | 21 Sep 2026 (announced) |
| Evidence Base | Pivotal Phase III Archway study + two supportive studies (Phase II Ladder; open-label long-term extension Portal) |
| Dosing Burden | Approximately two refills per year |
Drug Profile & Delivery Platform
- Active Molecule: Ranibizumab, a VEGF inhibitor designed to bind to and inhibit VEGF‑A, a protein shown to play a critical role in new blood vessel formation and vascular leakiness – the pathological drivers of nAMD.
- Customized Formulation: Susvimo is a customized formulation distinct from the ranibizumab intravitreal (IVT) injection marketed as Lucentis, optimized for sustained release from the implant.
- Contivue Platform: Comprises a refillable implant surgically inserted into the eye during a one‑time outpatient procedure, plus four ancillary devices to initially fill, insert, refill, and remove the implant.
- Delivery Mode: Contivue with Susvimo provides continuous delivery of the customized ranibizumab formulation over time, replacing repeated intravitreal injections with scheduled implant refills.
Clinical Evidence – Archway, Portal & Ladder Studies
| Endpoint / Measure | Result (Susvimo) | Comparator / Context | Outcome |
|---|---|---|---|
| Vision Outcomes (Archway, Phase III) | Achieved and maintained vision equivalent to monthly IVT ranibizumab injections | Monthly ranibizumab (Lucentis regimen) | Equivalence demonstrated |
| Long‑Term Vision Maintenance (Portal) | Vision maintained for up to seven years | Open‑label long‑term extension | Durable efficacy |
| Supplemental Anti‑VEGF Need | Approximately 95% of patients required no supplemental anti‑VEGF treatment with just two refills per year | – | High treatment durability |
| Long‑Term Safety | Well tolerated over the long term | – | Favorable tolerability profile |
The approval rests on data from three clinical studies in nAMD: the pivotal Phase III Archway study, the Phase II Ladder study, and the open‑label long‑term extension Portal study. In Archway, Susvimo‑treated patients achieved and maintained vision outcomes equivalent to monthly intravitreal ranibizumab injections, while longer‑term Portal data demonstrated that vision was maintained for up to seven years – with approximately 95% of patients needing no supplemental anti‑VEGF treatment on a two‑refill‑per‑year schedule.
Market Impact & Outlook
- Treatment Burden Revolution: For nAMD – a chronic condition that has traditionally demanded lifelong monthly or bimonthly intravitreal injections – a two‑refill‑per‑year implant dramatically reduces injection frequency, clinic visits, and patient burden.
- Adherence Advantage: Continuous delivery mitigates the real‑world vision loss associated with missed or delayed injections, addressing one of the largest effectiveness gaps in current nAMD care.
- Seven‑Year Durability Evidence: Portal’s demonstration of maintained vision for up to seven years provides the longest‑horizon efficacy dataset for a sustained‑delivery anti‑VEGF therapy, a powerful differentiator for payers, physicians, and patients.
- European Market Access: With EU approval secured, Roche can now pursue launch and reimbursement across European markets; country‑level pricing, reimbursement timelines, and launch sequencing – not disclosed.
- Franchise Synergy: Susvimo complements Roche’s existing ophthalmology portfolio, including Vabysmo (faricimab) and legacy Lucentis, broadening coverage across treatment paradigms in retinal disease.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding market launch, reimbursement outcomes, and commercial performance of Susvimo in Europe. Actual results may differ materially due to risks including pricing and reimbursement negotiations, competitive dynamics, and real‑world adoption.-Fineline Info & Tech
